SEC Form 4Coverage since Jun 25, 2026
$BEAM insider trading
Over the last 12 months, Beam Therapeutics insiders reported no purchases and 4 sales totaling $12.2M across SEC Form 4 filings. 75% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $12.2M 4 events
- Events · 12m
- 4 Form 4 filings, grouped
- Insiders · 12m
- 3 distinct reporters
- 10b5-1 share
- 75% pre-arranged plans
Side
Price · $BEAM · 12Mvia TradingView
Top insiders · 12m
Simon AmyChief Medical Officer2× · $442K
Evans John M.CEO1× · $1.7M
FMR LLC—1× · $10.0M
All insider trades
4 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | Simon AmyChief Medical Officer · O | ▼ Sale | 16,667 | $25.74 | $429K | -16.3% | plan |
| Jun 30, 2026 | Simon AmyChief Medical Officer · O | ▼ Sale | 373 | $34.73 | $13K | -0.4% | plan |
| Jun 30, 2026 | Evans John M.CEO · O·D | ▼ Sale | 50,000 | $34.9 | $1.7M | -4.6% | plan · 4 tranches |
| Jun 26, 2026 | FMR LLC10% | ▼ Sale | 284,860 | $35.24 | $10.0M | -25% | 2 tranches · indirect |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $BEAM feed.